A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors

被引：0
|
作者：
Desai, Jayesh
Davar, Diwakar
Deva, Sanjeev
Gao, Bo
Liu, Tianshu
Matos, Marco
Meniawy, Tarek
O'Byrne, Kenneth John
Sun, Meili
Voskoboynik, Mark
Yang, Kunyu
Yu, Xinmin
Chen, Xin
Dong, Yan
Giovinazzo, Hugh
Leaw, Shiangjiin
Patel, Deepa
Rahman, Tahmina
Wu, Yanjie
Day, Daphne
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] UPMC, Hillman Canc Ctr, Pittsburgh, PA USA
[3] Auckland City Hosp, Auckland Canc Trials Ctr Governance Grp, Auckland, New Zealand
[4] Harbour Canc & Wellness, Auckland, New Zealand
[5] Blacktown Hosp, Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[6] Fudan Univ, Affiliated Zhongshan Hosp, Shanghai, Peoples R China
[7] Pindara Private Hosp, Benowa, Qld, Australia
[8] Med Oncol Grp Australia, Sydney, NSW, Australia
[9] Australian Med Council, Canberra, ACT, Australia
[10] Med Board Queensland, Brisbane, Qld, Australia
[11] Linear Canc Res & Univ Western Australia, Nedlands, WA, Australia
[12] Princess Alexandra Hosp, Brisbane, Qld, Australia
[13] Queensland Univ Technol, Brisbane, Qld, Australia
[14] Jinan Cent Hosp, Jinan, Peoples R China
[15] Nucl Network & Monash Univ, Melbourne, Vic, Australia
[16] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[17] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[18] BeiGene USA Inc, Ridgefield Pk, NJ USA
[19] BeiGene USA Inc, Cambridge, MA USA
[20] BeiGene USA Inc, San Mateo, CA USA
[21] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[22] Monash Hlth, Dept Med Oncol, Clayton, Australia
[23] Monash Univ, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2574
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [2] Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
    Glisson, B. S.
    Leidner, R.
    Ferris, R. L.
    Powderly, J.
    Rizvi, N.
    Norton, J. D.
    Burton, J.
    Lanasa, M. C.
    Patel, S. P.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
    Desai, Jayesh
    Meniawy, Tarek
    Beagle, Brandon
    Li, ZheZhen
    Mu, Song
    Wu, John
    Denlinger, Crystal S.
    Messersmith, Wells A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
    Desai, Jayesh
    Voskoboynik, Mark
    Markman, Ben
    Hou, Jeannie
    Zeng, Dewan
    Meniawy, Tarek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
    Desai, J.
    Voskoboynik, M.
    Markman, B.
    Hou, J.
    Zeng, D.
    Meniawy, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 146 - 146
  • [6] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [7] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    Patnaik, Amita
    Kang, Soonmo Peter
    Tolcher, Anthony W.
    Rasco, Drew Warren
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Perez, Crystal
    Gergich, Kevin
    Lehnert, Manfred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    [J]. DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [10] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    [J]. INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
12345